Core Points - A class action lawsuit has been filed against Perrigo Company plc for alleged securities fraud and unlawful business practices [1] - Investors who purchased Perrigo securities during the Class Period can apply to be Lead Plaintiff by January 16, 2026 [2] - Perrigo reported significant financial challenges, including a 50% decline in earnings per share for fiscal year 2023 due to remediation costs in its infant formula business [2] - The company's stock price has experienced significant declines following negative earnings reports and strategic announcements, including a drop of 25.2% to close at $15.10 per share on November 5, 2025, after announcing a strategic review of its infant formula business [3] Financial Performance - For fiscal year 2023, Perrigo incurred one-time cash costs of $35 million to $45 million related to production issues in its infant formula business [2] - The adjusted gross profit for the second quarter ended June 28, 2025, decreased by $30 million, or 6.9%, attributed to production variability in infant formula [3] - The stock price fell by $4.87 per share (15.14%) on February 27, 2024, and by $3.28 per share (9.8%) on May 7, 2024, following negative earnings reports [2][3]

Core Viewpoint - Blue Owl Capital Inc. is under investigation for potential violations of federal securities laws following a report about blocking redemptions in one of its private credit funds, which may lead to significant losses for investors [1][2]. Group 1: Company Actions - Blue Owl Capital has blocked redemptions in its early private credit fund as it merges with a larger vehicle, which could result in investors permanently losing the ability to redeem cash at the fund's Net Asset Value (NAV) [2]. - After the announcement of the merger, Blue Owl's stock price experienced a decline of over 6% during intraday trading on November 17, 2025 [3]. Group 2: Financial Implications - Investors in Blue Owl Capital Corporation II will have to exchange their shares for publicly traded Blue Owl Capital Corporation shares, which are currently trading at a 20% discount to the fund's NAV [2].

Core Points - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged securities fraud related to the poor performance of its new sleep apnea device, Inspire V, which has been delayed in launch and has seen poor demand [2][4]. - The company significantly reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share down to $0.40 to $0.50 per share [2][3]. Company Performance - On August 4, 2025, Inspire disclosed issues with the launch of Inspire V, including inadequate training for treatment centers, software update delays, and excess inventory leading to poor demand [2][4]. - Following the announcement, Inspire's stock price dropped by $42.04, or 32.4%, closing at $87.91 per share on August 5, 2025, impacting investors negatively [3]. Legal Proceedings - The class action lawsuit alleges that the company made materially false and misleading statements regarding its business operations and prospects during the class period from August 6, 2024, to August 4, 2025 [4][5]. - Investors who purchased Inspire common stock during the class period are encouraged to file a lead plaintiff motion by January 5, 2026 [5].

Core Viewpoint - Telix Pharmaceuticals Limited is facing a class action lawsuit due to alleged securities fraud, with a deadline for investors to file a lead plaintiff motion by January 9, 2026 [1][5]. Summary by Sections Company Developments - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission (SEC) regarding its disclosures related to prostate cancer therapeutic candidates, leading to a stock price drop of $1.70, or 10.4%, closing at $14.58 on July 23, 2025 [2]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA concerning its Biologics License Application (BLA) for TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package. This announcement caused the stock price to fall by $1.95, or 16.1%, closing at $10.15 on the same day [3]. Allegations in the Lawsuit - The class action complaint alleges that during the Class Period, Telix's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects. Specific allegations include: 1. Overstating the progress made on prostate cancer therapeutic candidates. 2. Overstating the quality of Telix's supply chain and partners. 3. Misleading investors regarding the company's business and operational prospects [4].

Core Viewpoint - An investigation has been announced regarding Blue Owl Capital Inc. for potential violations of federal securities laws, indicating possible legal issues that may affect investors [1]. Company Summary - Blue Owl Capital Inc. is currently under scrutiny for alleged violations of federal securities laws, which may have resulted in financial losses for its investors [1]. - The Law Offices of Howard G. Smith are reaching out to investors who have suffered losses in Blue Owl Capital Inc. to discuss potential claims for recovery [1].

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for securities fraud, alleging that the company made misleading statements regarding its infant formula business and failed to disclose significant operational issues [1][11]. Summary by Sections Lawsuit Details - The lawsuit was filed in the U.S. District Court for the Southern District of New York on behalf of shareholders who acquired Perrigo securities between February 27, 2023, and November 4, 2025 [1]. - Plaintiffs are pursuing claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1]. Financial Performance and Issues - In November 2022, Perrigo acquired Nestlé's Gateway infant formula plant and the rights to the Good Start brand for $170 million [3]. - On February 27, 2024, Perrigo reported a 50% decline in earnings per share compared to the previous year, attributing this to remediation costs in the infant formula business, which were estimated to be an additional $35 million to $45 million [4]. - Following this announcement, Perrigo's share price fell by $4.87, or 15.14%, closing at $27.30 [5]. - On May 7, 2024, the company reported a 34.5% decrease in net sales for the first quarter, with gross margin declining by 90 basis points [6]. - The share price dropped by $3.28, or 9.8%, to close at $30.15 on the same day [7]. - On August 6, 2025, Perrigo disclosed that production issues led to scrapping approximately $11 million of inventory, resulting in a share price decline of $3.01, or 11.31%, to close at $23.61 [8]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and slashed its fiscal year 2025 outlook, cutting net sales growth guidance to -2.5% to -3% from a previous expectation of 0% to 3% [9]. - The stock price fell by $5.09, or 25.2%, to close at $15.10 on the same day [10]. Allegations in the Lawsuit - The lawsuit alleges that Perrigo's management made materially false and misleading statements and failed to disclose adverse facts about the infant formula business, including: 1. Significant underinvestment in maintenance and operational improvements [11]. 2. The need for substantial capital expenditures beyond stated estimates for remediation [11]. 3. Manufacturing deficiencies in the infant formula facility [11]. 4. Overstated financial results, including earnings and cash flow [11]. 5. Misleading positive statements regarding the company's business and prospects [11].

INSP SECURITIES ALERT: BFA Law Notifies Inspire Medical Systems, Inc. Investors of Important January 5 Securities Class Action DeadlineNovember 17, 2025 3:18 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a signifi ...

Core Viewpoint - Beyond Meat, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price, attributed to concerns over the valuation of its long-lived assets and an impending non-cash impairment charge [2][4][5]. Group 1: Stock Performance and Investigation - Beyond Meat's stock plummeted by approximately 23% on October 24, 2025, from $2.84 to $2.185 per share after the company announced expectations of a material non-cash impairment charge related to its long-lived assets [6]. - The company delayed its earnings announcement for the third quarter of 2025 on November 3, 2025, due to the need for additional time to complete the impairment review, which further contributed to a decline in stock value on that trading day [7]. Group 2: Legal Actions and Implications - Bleichmar Fonti & Auld LLP is leading the investigation into whether Beyond Meat inflated the value of certain long-lived assets, which may have misled investors [5]. - Investors in Beyond Meat are encouraged to seek legal options and may submit their information to the law firm for potential class action participation [8].

Core Viewpoint - A class-action lawsuit has been filed against James Hardie Industries plc, alleging securities fraud related to misleading information about inventory levels and customer demand in its North American segment [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Laborers' District Council & Contractors' Pension Fund of Ohio v. James Hardie Industries PLC., covers a class period from May 20, 2025, to August 18, 2025, and seeks damages for violations of the Securities Exchange Act of 1934 [2][3]. - The plaintiffs claim that James Hardie's North America Fiber Cement segment, which accounts for approximately 80% of total earnings, was misrepresented by management despite signs of inventory destocking [3][4]. Group 2: Allegations of Misrepresentation - Executives allegedly made false statements around May 20 and 21, 2025, claiming robust customer demand while denying any inventory destocking [4][5]. - The complaint suggests that sales were artificially inflated due to "inventory loading by channel partners," indicating potential fraudulent practices [4][5]. Group 3: Impact of Disclosure - On August 19, 2025, James Hardie disclosed a 12% decline in sales for its North America Fiber Cement division, attributing it to the customer destocking previously denied [5][6]. - Following this disclosure, the company's stock price fell by over 34%, leading to significant losses for investors [6][7]. Group 4: Investigation and Next Steps - Hagens Berman is investigating the claims and is seeking information from investors who may have suffered losses or possess relevant knowledge [7][8]. - Whistleblowers with non-public information are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program [9].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for alleged securities fraud affecting shareholders between August 6, 2024, and August 4, 2025 [2] Group 1: Lawsuit Details - The lawsuit claims that the company made false statements and concealed the poor demand for its new product, Inspire V, which was launched unsuccessfully due to significant surplus inventory and reluctance from providers to adopt the new treatment [3] - The complaint highlights that the company failed to complete essential tasks for a successful launch, including training and onboarding for treatment center customers, setting up IT systems, updating insurer claims software, and ensuring Medicare reimbursement was in place [3] Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4] Group 3: Legal Firm Background - Levi & Korsinsky LLP, the firm handling the lawsuit, has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States [5]